Hepatitis B Vaccine 2025 Update: Schedule, Side Effects & Cost

A sweeping change to U.S. infant immunization policy emerged today as the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) voted to withdraw its 1991 recommendation that every newborn receive a first dose of the hepatitis B vaccine within 24 hours of birth. Instead, the committee urged individualized, risk-based decision-making—a position praised by Health and Human Services Secretary Robert F. Kennedy Jr., who campaigned on giving parents more autonomy over early-life vaccinations. The 12-to-4 vote caps a months-long review of surveillance data showing that perinatal hepatitis B transmission rates have remained historically low for more than a decade, thanks largely to universal prenatal screening that flags expectant mothers with active infections. Panelists argued that maintaining rigid, one-size-fits-all guidance imposes unnecessary medical interventions on the majority of parents whose babies face minimal exposure risk at birth. The new policy still “strongly encourages” vaccination for infants born to hepatitis B-positive mothers and for households with high-risk contacts, but it leaves timing and dosing to clinical discretion. Public-health advocates reacted swiftly. The American Academy of Pediatrics warned that dropping the birth-dose default could erode nationwide coverage rates, noting that 80 percent of U.S. infants currently receive the first shot before hospital discharge. “We risk reopening the door to silent infections that only surface decades later as liver cancer,” said Dr. Mia Alvarez, chief of pediatric infectious diseases at Emory University Hospital. Pharmaceutical manufacturers, meanwhile, said supply chains are unlikely to shift in the short term; the United States purchases roughly 3 million pediatric hepatitis B doses annually, split among two recombinant vaccines—Engerix-B and Recombivax HB—and the newer CpG-adjuvanted Heplisav-B, which is licensed for adults but often discussed as a future pediatric option. Globally, the World Health Organization still calls the hepatitis B birth dose “a critical pillar” of its plan to eliminate viral hepatitis by 2030, pointing to evidence from Taiwan and sub-Saharan Africa where universal newborn vaccination drove chronic infection rates below 2 percent in children under five. ACIP members acknowledged those data but argued that the United States’ advanced prenatal screening infrastructure justifies diverging from WHO’s blanket strategy. Hospitals and birthing centers now have 90 days to update consent forms, electronic health record prompts and staff training before the revised schedule appears in the CDC’s 2026 immunization guidelines. States that mandate adherence to the CDC schedule for school entry will also need to amend regulations, setting up potential legal and legislative battles in early-adopting jurisdictions such as California and New York. For parents weighing the new approach, clinicians emphasize three key points: 1. Mothers should confirm hepatitis B surface antigen testing results are documented during pregnancy. 2. Babies born to hepatitis B-positive or high-risk mothers still need both passive immune globulin and the first vaccine dose within 12 hours of birth. 3. Families opting to delay must plan timely follow-up, because the full three-dose series remains essential before kindergarten to ensure lifelong protection. The decision underscores a broader national debate: where to balance individual choice with population-level disease control. As the U.S. re-charts its path on hepatitis B prevention, epidemiologists will be watching state surveillance dashboards for any uptick in infant infections that could force a policy course-correct.